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Abstract
Background: Cancer survivors are at risk of developing second and subsequent primary cancers, referred to as
multiple primary cancers (MPCs). It is not clear whether the risk of MPCs has increased over recent decades, but
increasing use of radiological imaging and potentially harmful effects of certain cancer treatments raise this
possibility. A systematic review was undertaken to assess whether there has been a temporal change in the risk of
developing MPCs.
Methods: A systematic search to identify population-based studies of MPCs was performed in Medline/PubMed
and Embase databases from inception to August 2016. Included studies were those reporting risk of MPCs for all
sites combined following a first cancer at any site or a specific site, using standard incidence ratios (SIRs) or
equivalent, and with analysis stratified by calendar years.
Results: We identified 28 articles eligible for inclusion, comprising 26 population-based studies and two
monographs. MPC incidence was reported in nearly 6.5 million cancer survivors. For all first cancer sites combined,
a higher rate of MPCs was reported in more recent than earlier calendar periods in four of the six relevant studies.
The SIRs ranged from 1.14 for a first cancer diagnosis in the early 1980s to 1.21–1.46 in the late 1990s in the USA
and Australia. Two studies from Italy and France showed no significant difference in SIRs across time periods 1978–
2010 and 1989–2004. The remaining 22 studies reported various temporal trends in the risk of developing MPCs
after a first cancer at a specific site, but most showed little change.
Conclusion: Overall, the risk of developing MPCs appears to have increased since the 1980s when considering
studies of all primary cancer sites combined from the USA and Australia but not from Europe. With the introduction
of more routine nuclear medical imaging over the last 15 years, more studies are needed to confirm recent trends
of MPC risk in adult cancer survivors.
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Background
Survival for most cancers has increased steadily over
the last three decades, mainly due to increased detec-
tion of early-stage cancers and advances in cancer
treatment [1, 2]. This has been a global phenomenon
and has led to a growing number of cancer survivors
worldwide [3, 4]. Increasing attention has been given
to the long-term outcomes of cancer survivors includ-
ing the risk of developing new primary cancers [5, 6].
In a seminal report from the USA, up to 10 % of
cancer survivors were diagnosed with a second or
higher-order primary cancers during a 27-year period
1973 to 2000 [7]. A higher rate of new cancers was
observed among cancer survivors with a first cancer
diagnosed in more recent (between 1995 and 2000)
than in earlier time periods (1973–79).
Two or more primary cancers occurring in the same
individual that are neither extensions, recurrences nor
metastases of each other are defined as Multiple Primary
Cancers (MPCs) [8]. Factors associated with any change
in the risk of developing MPCs might include increased
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use of diagnostic imaging and adverse cancer treatment
effects. The past 30 years has seen a large increase in the
use of diagnostic imaging, particularly radiologic medi-
cine examinations such as diagnostic X-rays and com-
puted tomography (CT) scanning [9–11]. Medical
radiation exposure to the USA population has increased
approximately 600 % since the 1980s [12]. In addition,
cancer survivors tend to receive more frequent radio-
logic imaging than the general population due to follow-
up care after primary treatment [13–15]. The rising use
of various imaging modalities might be expected, there-
fore, to increase the possibility of incidental findings of
new cancers during a routine follow-up examination
and/or may increase the future risk of cancer due to the
radiation exposure [16].
Some MPCs may also be treatment-related [17, 18].
Patients treated with radiotherapy and some specific
chemotherapeutics can experience a number of signifi-
cant late effects. One of the most serious potential long-
term side effects is the development of MPCs [19–21].
The risk of developing MPCs is increased among survi-
vors treated with radiotherapy, alkylating agents, anthra-
cyclines and epipodophyllotoxins [3, 21–23]. A mutation
in a susceptibility gene may also promote two or more
cancers in an individual [22–24]. However, genetic risk
factors for MPCs would not be expected to change over
recent decades, unless they interact with other risk fac-
tors that demonstrate temporal trends.
In order to better understand temporal trends in the
risk of developing MPCs, we performed a systematic re-
view of the scientific literature to determine whether the
risk of MPCs has increased over recent decades.
Methods
Scope of the review
We conducted a systematic literature search to identify
studies describing adult cancer survivors with the diag-
nosis of MPCs. The review was focused on the following
question: has there been an increase in the risk of devel-
oping MPCs over time?
Search strategy and selection criteria
We used two approaches to conduct the systematic
search in two phases (Table 1). The original review was
conducted in PubMed and Embase databases for eligible
articles published prior to 1st March 2015. The update
was conducted to August 2016. The MeSH terms related
to “multiple primary cancers” and “second cancers” and
related subcategories were used in separate searches:
Neoplasms/Multiple Primary, Neoplasms/Second Primary
and epidemiology/prevention and control. A number of
key words (“multiple primary cancer* or malignanc* or
tumo*”, “population-based” and “time period* or interval*
or calendar years”) were also used and combined in differ-
ent databases.
Following the Preferred Reporting items for Systematic
reviews and Meta-analyses (PRISMA) statement [25, 26],
eligibility criteria for included studies were as follows: (i)
Type of studies: published population-based studies and
reports published in English; (ii) Types of patients: adult
cancer survivors (≥19 years) who were diagnosed with a
first primary cancer (index cancer); (iii) Types of out-
comes measures: adult cancer survivors (≥19 years) who
developed a second or higher-order primary cancer (all
sites combined). Studies of cancer survivors who devel-
oped MPCs at a specific site and studies based on aut-
opsy cases were excluded because we were interested in
the overall MPC risk among adult cancer survivors.
Studies of MPCs in patients undergoing specific therap-
ies or by treatment periods were also excluded given we
were interested in all factors that affected the trends in
MPC risk rather than treatment effects only.
Data extraction and analysis
Titles and abstracts of identified articles were assessed
against the inclusion criteria by one author (YY). The
full text of potentially relevant studies and the reference
lists of included studies were read to identify further ori-
ginal articles. Two authors (YY and AV) developed an
extraction sheet to record first author’s name, publica-
tion year, source of data, the number of Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) criteria met, site of first primary cancer, study
period and follow-up, study size, study population (def-
inition and inclusion criteria), definition of MPCs, calen-
dar year of first cancer diagnosis, and the standardised
incidence ratios (SIRs) or relative risks (RRs) and 95 %
confidence intervals (95 % CIs) for MPCs by time pe-
riods. Typically, SIRs were derived from the observed
number of MPCs divided by the expected number (O/
E), with the expected number calculated from age-, sex-
and calendar year- specific incidence rates in the general
population [7, 27]. Alternatively, RRs were calculated as
the risk of MPCs occurring in one time period compared
with a reference period [28].
The Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) criteria were used to
assess the strengths, weaknesses, and generalizability of
included studies [29]. The STROBE statement was de-
veloped to help readers when critically appraising pub-
lished articles. Two authors (YY and AV) used a
modified checklist of items for cohort studies to assess
the number of criteria met in each study. We evaluated
the coding rules of MPCs (i.e. Surveillance, Epidemi-
ology, and End Results (SEER) [30] or International As-
sociation of Cancer Registries (IACR) and the
International Agency for Research on Cancer (IARC)
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(IARC/IACR) [8] coding rules for MPCs) applied in each
study as the diagnostic criteria in the STROBE checklist
(Additional file 1).
Table 1 Search strategy for Medline and Embase (1 March 2015)
Approach 1
Search strategy using MeSH terms in Medline
No. Search
1 “Neoplasms, Multiple Primary/epidemiology”[Mesh] OR "Neoplasms,
Multiple Primary/prevention and control"[Mesh] OR "Neoplasms,
Second Primary/epidemiology"[Mesh] OR "Neoplasms, Second




Search strategy using keywords in Medline
1 multiple primary cancer*[Title/Abstract]
N = 576
2 multiple primary malignanc*[Title/Abstract]
N = 208
3 multiple primary tumo*[Title/Abstract]
N = 386










9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
N = 4,801
10 time[Title/Abstract] OR period*[Title/Abstract] OR interval*[Title/






13 #9 AND #10 AND #11 AND #12
N = 302
17 Limits: adult: 19+ years
N = 236
Search strategy using keywords in Embase
1 Multiple AND primary AND (‘cancer’/exp OR cancer) OR multiple
AND primary AND malignanc* OR multiple AND primary AND
tumor* OR multiple AND primary AND carcinoma* OR second AND
(‘cancer’/exp OR cancer) OR second AND malignanc* OR second
AND tumor* OR second carcinoma*
N = 236,978
Table 1 Search strategy for Medline and Embase (1 March 2015)
(Continued)
2 Time AND period* OR time AND interval* OR calendar AND year*
N = 691,550
2 #1 AND #2 AND population AND risk AND [embase]/lim
N = 457
Approach 2
Search strategy using MeSH terms in Medline
No. Search
1 "Neoplasms, Multiple Primary"[Mesh] OR "Neoplasms, Multiple
Primary"[Mesh] OR "Neoplasms, Second Primary"[Mesh] OR




Search strategy using keywords in Medline
1 multiple primary cancer*[Title/Abstract]
2 multiple primary malignanc*[Title/Abstract]
3 multiple primary tumo*[Title/Abstract]





9 second primary cancer*[Title/Abstract]
10 second primary malignanc*[Title/Abstract]
11 second primary tumo*[Title/Abstract]
12 second primary carcinoma*[Title/Abstract]
13 second primary cancer*[Title/Abstract]
14 second primary malignanc*[Title/Abstract]
15 second primary tumo*[Title/Abstract]
16 second primary carcinoma*[Title/Abstract]
17 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR
#11 OR #12 OR #13 OR #14 OR #15 OR #16
N = 12,841




21 #17 AND #18 AND #19 AND #20
N = 232
17 Limits: adult: 19+ years
N = 186
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Results
Literature search
The defined search criteria identified 1832 relevant articles
and four were added through manual review of references.
Of the 225 articles assessed as eligible for full-text review,
23 articles met the inclusion criteria and were included in
the narrative synthesis. After combining five eligible arti-
cles in the updated search, 28 studies were included in the
final analysis comprising 26 population-based studies and
two monographs (Fig. 1).
Study characteristics
All 28 included studies were population-based, published
between 1987 and 2015, presenting data from Europe,
North America, Australia and Japan (Table 2). 26 were
peer-reviewed publications, reporting on more than 2.8
million survivors of adult cancer over the period of 1943
to 2012 [31–56], with 178,091 MPCs identified. Four of
them reported the risk of developing MPCs following
first cancer with all sites combined [45, 46, 48, 52].
Others focused on the risk of MPCs following first can-
cer at a specific site. The remaining were two mono-
graphs from the USA and Italy. One was a SEER
monograph that used data from nine cancer registries in
the USA, reported on more than 2 million cancer survi-
vors during the follow-up period from 1973 to 2000, and
a total of 185,407 MPCs were observed [7]. The other
was a monograph of the Italian Association of Cancer
Registries (AIRTUM), using data from 38 general and
five specialised cancer registries in Italy, that reported
Fig. 1 Flow diagram of study selection
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Study population: definition and
inclusion criteria












Curtis RE et al.
(2006) [7] SEER,
U.S.




185,407 The study population includes nearly
2 million cancer patients reported to
the 9 SEER registries from 1973 to
2000, with follow-up for subsequent
cancer occurrence extending up to
27 years.




















27/30 Any site 1976-
2010
1,635,060 85,399 This monograph uses data from the
AIRTUM Database (at December 2012)
regarding all cancer cases, except
non-melanoma skin cancer, diagnosed
between 1976 and 2010 in the gen-
eral cancer registries.






















289,967 21,226 All patients presenting with a first
cancer diagnosed between 1989 and
2004, excluding non-melanoma skin
cancers.






















204,962 23,580 All patients diagnosed with a first
primary invasive cancer between 1982
and 2001 who survived for a
minimum of 2 months, restricting to
15 years or older at the time of first
diagnosis.
MPC coding rules: Included
histologically similar cases of cancer
at the same body site. Excluded
synchronous primary cancers (those




























Table 2 MPCs following a first primary cancer at any site or a specific site (Continued)




22/30 Any site 1953-
1991
470,000 19,800 All 470,000 patients registered in
Finland from 1953 to 1991 with
malignant neoplasms [primary site
codes 140–208 in the International
Classification of Diseases (ICD-7), WHO,
19571 excluding basal-cell carcinomas
of the skin, carcinoma in situ of the
uterine cervix, and papilloma of the
urinary organs.

























217,307 4,436 All reported cases aged 0–79 who
were initially diagnosed with a first
primary cancer (invasive cancer and
benign intracranial tumour)


















leukaemia, lymphoma and myeloma












2,753 145 All adult cases of CML as a primary
diagnosis (ICD-7 code 205.1, age at
diagnosis≥ 18 years) arising between
January 1, 1970, and December 31,
1995.

















12,373 1,105 All patients with chronic lymphocytic
leukaemia (ICD-7-code 204.0)


















3104 358 All hairy cell leukaemia patients who
survived for at least 2 months after
diagnosis.


















Table 2 MPCs following a first primary cancer at any site or a specific site (Continued)










952 49 Patients were recorded in the Italian
Registry of HCL between January 1981
and December 1996.




























2,970 58 All patients registered with Hodgkin’s
disease in the South Thames Cancer
Registry during the period 1961–80.
Excluded patients if they had had
another tumour registered either
before or at the same time as the
index tumour, or if their index tumour
had been registered at death (no
follow-up) or at age 85 years or more.
Second cancer defined as the site
and the histology are distinct from
the first. Second cancers at the
same site as the first or at a different
site but with the same histology as
the first will be registered only if the
hospital record or pathology report
explicitly states that it is a new
primary, distinct from the previous
cancer.
Excluded second tumours occurring


















6815 Almost all histologically confirmed
cases of non-Hodgkin lymphoma.





























7,546 580 NHL patients was extracted from the
K2 France cohort, which includes
cancer cases diagnosed between 1989
and 2004 recorded by 10 French
populationbased cancer registries.
Patients who developed a
synchronous second cancer (<61 days
of follow-up) were excluded.
MPC coding rules: A Second Primry
Cancer was defined as the first
subsequent primary cancer
occurring at least two months

























Table 2 MPCs following a first primary cancer at any site or a specific site (Continued)







36,491 2021 All cases were identified by site code
ICD-0-3: C9732 and C9734.
Excluded cases whose reporting
sources were coded as autopsy or
death-certificate-only (n = 775), cases
where MM was not the first primary
(n = 3545) and cases with second can-
cer diagnosed within the first
2 months of MM diagnosis (n = 365)








All second cancers except cancers






Breast and ovarian cancer
Mellemkjaer L et






26/30 Breast cancer 1943-
2000
525,527 31,399 All women with a first primary breast
cancer (ICD-9 5 174) except patients
for whom the first primary cancer
diagnosis and death were recorded at
the same time or who had 2 first
primary cancers recorded
simultaneously (same dates of
diagnosis).






Second cancers except contralateral
breast cancer, brain and nervous
system only included malignant
tumours, bladder cancer included















27/30 Breast cancer 1943-
2002
376,825 23,158 All women diagnosed with a first
primary cancer of the breast between
January 1, 1943 and December 31,
2002 who survived at least 1 year.
MPC coding rules: Subsequent
primary non-haematological malig-
nancies (except breast cancer) that









et al. (2013) [38]
Granada Cancer
Registry, Spain
26/30 Breast cancer 1985-
2007
5897 314 All cases were identified by site code
ICD-O-3 (C50).




Exclude patients whose first primary
cancer diagnosis and death were
recorded simultaneously and
synchronous first primary cancers.
All second primary cancers except
contralateral breast cancer which

















11,802 170 All patients registered with cancer of
the ovary in the South Thames Cancer
Registry during the period 1961–80.
Excluded patients if they had had
another tumour registered either
before or at the same time as the
index tumour, or if their index tumour
had been registered at death (no
follow-up) or at age 85 years or more.
Second cancer defined as the site
and the histology are distinct from
the first. Second cancers at the
same site as the first or at a different
site but with the same histology as
the first will be registered only if the
hospital record or pathology report
explicitly states that it is a new
primary, distinct from the previous
cancer.
Excluded second tumours occurring

















Table 2 MPCs following a first primary cancer at any site or a specific site (Continued)
Thyroid cancer








178,844 2,895 Records code C73.9 starting in January
1993 through
December 2010. Patients who
developed a second malignancy
within the first 2 months of follow-up
(n = 628) were excluded.






















52,103 4457 All cases were identified by site code
ICD-0-3: C739, reported to a SEER 9
database
between 1973-2008
MPC coding rules: SEER
All second cancers
except cancers within the first two


























55,378 2,578 Patients diagnosed with a first
prostate cancer between 1993 and
2011. Excluded patients who
presented with a SPC within two
months of their first prostate cancer
diagnosis, patients with subsequent
prostate cancer after the diagnosis of
another primary cancer, and patients
for whom only death certificate
information was available.















4,503 380 Cases of first diagnosed prostate
carcinoma registered between 1974
and 1994 with histologic confirmation
available for 89.7 %.






Other sites (malignant meningioma, head and neck, oesophageal, ocular melanoma, merkel cell, colorectal cancer, bladder, testis)






1,603 56 All patients in the SEER database with
the diagnosis of malignant
meningioma were identified via SEER
program 6.6.2 (1973–2007).

















7,329 1,326 All patients were followed-up for
10 years or until December 31, 2006.
HNSCC included here were

















histology codes 8070–8076, 8078) lo-
calized at the oral cavity, oropharynx,
hypopharynx and larynx (ICD-O-3 site
































24,557 985 All oesophageal cancer patients who
survived for at least 2 months after
diagnosis.
MPC coding rules: SEER





















10,396 1,029 All cases of ocular melanoma without
stratifying by subsite.



















1,306 122 All patients with a first primary
cutaneous MCC in 1 of 11 population-
based cancer registries of SEER pro-
gram (1986–2002).
MPC coding rules: SEER
Subsequent primary cancers were
invasive primary neoplasms that
developed at least 1 month after a
diagnosis of MCC. Excluded

















240,584 27,731 Invasive CRC patients who were
diagnosed




at the age of more than 20 years.
Excluded patients: 1) diagnosed with
unknown age, 2) reported only on
death or autopsy certificate only, 3)
being stage of in situ. SPMs
diagnosed during six months period






















Table 2 MPCs following a first primary cancer at any site or a specific site (Continued)












10,047 1,291 All patients with a first bladder cancer
(BCa) diagnosed between 1989 and
2004 and followed up to 31
December 2007. Excluded patients
with a known history of previous
cancer before BCa diagnosis




























2,013 27 All patients registered with cancer of
the testis in the South Thames Cancer
Registry during the period 1961–80.
Excluded patients if they had had
another tumour registered either
before or at the same time as the
index tumour, or if their index tumour
had been registered at death (no
follow-up) or at age 85 years or more.
Second cancer defined as the site
and the histology are distinct from
the first. Second cancers at the
same site as the first or at a different
site but with the same histology as
the first will be registered only if the
hospital record or pathology report
explicitly states that it is a new
primary, distinct from the previous
cancer.
Excluded second tumours occurring







STROBE Strengthening the Reporting of Observational Studies in Epidemiology, MPCs multiple primary cancers, N number of patients, SEER Surveillance, Epidemiology, and End Results, IARC/IACR International
Association of Cancer Registries (IACR)/the International Agency for Research on Cancer (IARC), CI confidence interval, ICD International Classification of Diseases, CML chronic myeloid leukaemia, CLL chronic











on more than 1.6 million cancer survivors during the
period of 1976–2010 with 85,399 MPCs identified [57].
The coding rules to define MPCs varied across studies.
Seven studies and the SEER monograph used incidence
and follow-up data from SEER program registries, and
employed SEER coding rules [7, 39–44, 53]. Eight studies
and the Italian monograph used coding rules proposed by
the IARC/IACR [37, 38, 45, 47, 48, 50, 52, 56, 57]. While
it may be difficult to directly compare risk estimates
derived using different coding rules, comparisons of
temporal trends will be valid if the rules used to de-
fine MPCs are consistent over time within a single
study population [58].
Study quality
The number of STROBE criteria met in all population-
based studies ranged from 18 to 28 of 30 items in total,
with 21 studies meeting at least 25 criteria. Included
studies had various objectives, data sources, study sizes
and STROBE criteria met, but they all reported the risk
of MPCs over different time periods.
Risk of MPCs following first primary cancer with all sites
combined
Six studies reported temporal trends in MPC risk among
survivors of adult cancer with all first cancer sites com-
bined. Four of them observed an increasing trend in
MPC risk from earlier to more recent periods. The SEER
monograph reported a 14 % higher risk of developing
MPCs than would be expected in the general SEER
population during the 25 years of follow-up, with a total
of 185,407 observed MPCs compared with 162,602 ex-
pected (SIR, 1.14; 95 % CI, 1.14 to 1.15). There was an
increasing trend of SIRs rising from 1.12 with periods of
first cancer diagnosis during 1973–79 to 1.21 during
1995–2000 [7]. Three large population-based studies
from Australia, Finland and Japan (Australia and Japan
including more than 200,000 cancer survivors, Finland
including 470,000 cancer survivors) also showed an in-
crease in the risk of developing MPCs across the whole
study period when all first cancer sites are combined. In
Australia, the SIRs grew from 1.14 with periods of first
diagnosis in 1982–1986 to 1.46 in 1997–2001 [46]. In
Finland, the SIRs increased from 1.09 in the 1950s to
1.14 in the 1980s [52]. In Japan, the relative risk in-
creased from 1.00 in 1966–1971 (reference) to 2.89 in
1984–1986 [45]. However, two studies from Italy and
France showed no significant difference in SIRs across
different time periods. The Italian monograph reported
SIRs of 1.10 in 1978–1987, 1.08 in 1988–1997 and 1.10
in 1998–2010, with a 10 % higher risk of developing
MPCs than expected across the entire study period
1976–2010 (SIR, 1.10; 95%CI, 1.09 to 1.10) [57]. The
French study was a large population-based study using
data from 10 French population-based cancer registries,
with a first cancer diagnosis between 1989 and 2004 [48].
Risk of MPCs following first primary cancers at specific
sites
The risk of MPCs following first cancers at specific sites
did not differ significantly across calendar periods of first
cancer diagnosis in 14 studies [33, 35, 36, 38–41, 43, 44,
47, 49–51, 55]. Six studies reported an increasing tem-
poral trend in MPC risk [32, 34, 42, 53, 54, 56], whilst
two studies reported a decreasing trend in MPC risk
after breast cancer during the study period 1943–2000
[31, 37]. There were a total of three studies on breast
cancer as the first cancer.
MPCs following leukaemia, lymphoma and myeloma
Eight studies assessed the risk of MPCs following first
cancers of the hematopoietic and lymphoid system
[32, 34–36, 40, 43, 51, 54]. The risk of MPCs did not
reveal any particular trends with respect to variations
in SIRs over time in either of two major leukaemia
(chronic myeloid leukaemia, chronic lymphocytic leu-
kaemia) [35, 36] or the uncommon hairy cell leukae-
mia [40, 51]. These studies compared the risk of
MPCs before and after a time point around 1990
when novel therapeutics such as interferon, fludara-
bine and other nucleoside analogues were introduced.
Three studies with first cancers of Hodgkin or non-
Hodgkin lymphoma reported an increasing trend in
the risk of MPCs over time [32, 34, 54]. The risk of
MPCs increased from 1.2 in the 1960s to 1.6 in the
1970s among 3139 cases of Hodgkin’s disease [32].
For MPCs following non-Hodgkin lymphoma (NHL),
the risk was higher in the time interval of 2000–2006
(RR = 1.00, reference) than in 1980–1984 (RR = 0.65;
95%CI: 0.59-0.72) in more than 60,000 registered
cases from three Nordic countries [34]. A similar pat-
tern was also confirmed in France. The risk of MPCs
was 1.37 (95%CI: 1.08-1.74) times higher for NHL
diagnoses in 2000–2004 than in the 1989–1994 refer-
ence category [54]. For MPCs following multiple mye-
loma, there was no significant change in the risk
before and after 2000. However, the overall risk of
MPCs was also not significant (SIR = 0.98; 95 % CI:
0.94–1.02) [43].
MPCs following breast and ovarian cancer
No statistically significant change or decreasing trends
in MPCs risk was observed in three breast cancer stud-
ies, two from multicentre studies and one from a single
cancer registry [31, 37, 38]. One large multicentre study
used data on 525,527 breast cancer survivors from 13
population-based cancer registries from Europe,
Australia, Canada and Singapore covering the study
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period 1943–2000. The risk of MPCs decreased from
1.32 (95%CI 1.30-1.35) before 1975 to 1.18 (95%CI 1.14-
1.22) after 1991 [37]. Another multicentre study encom-
passing four Scandinavian cancer registries reported data
on more than 300,000 one-year survivors of breast can-
cer during a similar period, 1943–2002. The risk of
MPCs was lower after 1980 than before (SIR = 1.09 and
1.19, respectively). However, second haematological can-
cers were excluded from the analysis [31]. No significant
change in trend was observed in a study from a single
cancer registry in Spain during the period of 1985–2007
(SIR 1.37, 95%CI 1.16-1.58 in 1985–1995 and SIR 1.41,
95%CI 1.18-1.64 in 1996–2007) [38]. The risk of MPCs
following ovarian cancer increased from 1.1 in 1961–69
to 1.2 in 1970–80 (no 95%CI provided), using data from
a single cancer registry in the UK. However, the ob-
served numbers were mostly too small to obtain reliable
estimates [32].
MPCs following thyroid cancer
In the USA, the risk of MPCs was higher in patients di-
agnosed with a first thyroid cancer during 2004–2008
(SIR 1.45, 95%CI 1.28-1.62) than in 1973–1983 (SIR
1.02, 95%CI 0.97-1.07) [42]. In Korea, however, the risk
only reached statistical significance for a first thyroid
cancer diagnosis between 2003 and 2007 (SIR 1.09,
95%CI 1.03-1.15), with smaller increases in other periods
(SIR = 0.92 in 1993–1997, 1.05 in 1998–2002 and 1.06 in
2008–2010) [49].
MPCs following prostate cancer
Interestingly, the risk of MPCs following a first prostate
cancer was significantly lower than expected in two rele-
vant studies from the USA and Korea [33, 55]. The value
of SIRs was consistently 0.7 from 1974 to 1994 using
data from SEER (USA) cancer registries [33] and ranged
from 0.6 to 0.7 during 1993–2011 using data from a na-
tionwide hospital-based cancer registry in Korea [55].
MPCs following first cancers at other sites
From the early 1970s to the mid-2000s, the temporal
trends in the risk of MPCs did not change significantly
with a first cancer diagnosis of malignant meningioma,
oesophageal cancer and ocular melanoma [39, 44, 47],
but varied for first cancer at head and neck [50]. The
risk of MPCs following testicular cancer remained con-
sistent and lower than expected from 1961 to 1980. Al-
though the SIRs for first cancer of Merkel Cell
carcinoma increased from 1.09 (95%CI 0.83-1.70) in
1986–1994 to 1.37 (95%CI 1.05-1.76) in 1995–2002, the
increase was not statistically significant [41]. For
MPCs following colorectal cancer and bladder cancer,
both risks increased with the year of first cancer diag-
nosis. The SIRs increased significantly from 1.53
(95%CI 1.37-1.71) in 1989–1992 to 2.02 (95%CI 1.79-
2.27) in 2001–2004 for first bladder cancer [56]. For
first cancer at colon and rectum, the SIRs were higher in
2002–2012 (1.25 for colon, 1.16 for rectum) than in
1992–2001 (1.08 for colon, 1.00 for rectum) [53].
Discussion
To our knowledge, this is the first systematic review fo-
cusing on the temporal trends in the risk of MPCs.
There was an increasing time trend in the risk of devel-
oping MPCs in the USA and Australia when all first can-
cer sites were combined. Risk increased from 1.12 to
1.14 following a first cancer diagnosis in the early 1980s,
to 1.21-1.46 in the late 1990s. In European countries, the
risk remained similar during 1978–2010 for Italian can-
cer survivors and showed no significant change between
1989 and 2004 for French cancer survivors. Three po-
tential explanations are postulated for the increasing
trends in the USA and Australia: 1) increased detection
of MPCs, both intended and incidental; 2) increased ra-
diation exposure and 3) changed cancer treatments. The
trends in the risk of developing MPCs varied by site of
first cancer from 1943 to 2012, but mostly there was lit-
tle change.
Increased detection
Increasing risk of MPCs might be a result of increased
detection arising from the introduction of cancer screen-
ing programs for the early detection of cancers in the
community; and incidental findings arising from the in-
creased use of sensitive imaging tests in the routine clin-
ical follow-up of cancer survivors. Early detection and
incidental findings are not necessarily of benefit, as they
can lead to “overdiagnosis”. Overdiagnosis is the detec-
tion of a “cancer” that would not cause symptoms or
death in a patient’s lifetime [59].
Higher MPCs risk was observed in studies from the
USA and Australia in the late 1990s [7, 46]. These
findings coincide with the introduction of national
cancer screening programs for cervical cancer and
breast cancer in Australia in the early 1990s [60]. In
the USA, the use of cancer screening for cervical can-
cer, breast cancer, colorectal cancer and prostate can-
cer has increased since 1987, particularly for breast
cancer [61–63]. As well as providing benefits, screen-
ing has led to the overdiagnosis of non-progressive or
low progressing cancers [64–67].
Cancer survivors are considered at increased risk for
future cancers, and screening has been specifically rec-
ommended for survivors of some cancer types [68]. A
meta-analysis of 20 studies demonstrated that cancer
survivors tended to receive more frequent screening for
new primary cancers, especially for breast, cervical, colo-
rectal and prostate cancer than non-cancer controls
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[69]. This may thus differentially lead to increased detec-
tion among cancer survivors compared with the general
population.
Another activity leading to a higher rate of MPCs
may be the increased use and improvements in diag-
nostic imaging in recent time periods. The use of
diagnostic imaging, especially computed tomography
(CT) scans, has increased dramatically worldwide
since 1980, particularly in the USA, Australia and
Japan [9, 11, 70]. Cancer survivors routinely undergo
CT scanning and other imaging procedures during
follow-up, the detection of a new primary cancer,
therefore, becomes more likely than in the general
population with no prior cancer diagnosis [71]. Some
of these incidental findings might be clinically unim-
portant, leading to overdiagnosis [10, 59, 72].
Increased radiation exposure during the follow-up after a
first cancer diagnosis
Radiation exposure due to monitoring may of itself lead
to harmful effects [73]. This possibility is consistent with
our finding that the highest risk of MPCs, from the late
1990s, has occurred since radiation exposure has in-
creased enormously [9]. Since the 1980s, the average an-
nual per-capita effective dose from medical radiological
procedures doubled worldwide [9, 11]. In the USA, the
average annual per capita dose for medical procedures
increased almost six-fold from 0.5 mSv in 1980 to
3.0 mSv in 2006 [9], with X-rays and CT scan the two
most common imaging procedures leading to radiation
exposure [11].
The lifetime risk of cancer attributable to diagnostic
X-rays is estimated to vary between 0.6 and 1.8 % across
15 countries, including the USA and Australia, between
1991 and 1996 [74]. In Japan, the attributable risk has
been estimated at 3.2 %, but the Japanese results are
confounded by the impact of background radiation fol-
lowing the atomic bombings in World War II [74].
CT scanning has been widely used since the 1990s
and delivers a much higher radiation dose than diag-
nostic X-rays [75]. In Australia, the cancer risk in
children and adolescents who underwent CT scanning
between 1985 and 2005 was found to be 24 % higher
than in their peers who did not undergo CT scanning
[16]. The impact on lifetime risk could not be ascer-
tained given that cancer excess was still occurring at
the end of the study. Increased risk of cancer due to
CT scanning is not, however, limited to children.
Adults are also at increased risk of cancer from the
radiation exposure [76]. Imaging-based evaluation, es-
pecially CT scans, is the preferred modality to assess
response to treatment, and for routine surveillance of
most cancer survivors [77]. Therefore, increased risk
of MPCs could be partly attributable to cumulative
radiation exposure due to recurrent CT scans [78].
Changed cancer treatments
Studies of MPCs consequent to a primary cancer at a spe-
cific site can help us understand the impact of treatment
changes on trends of MPC risk. No statistically significant
change in risk of MPC was observed in most specific site
studies, including after the 1990s when many newer (and
improved) treatments or management strategies were in-
troduced [33, 35, 36, 38–41, 43, 44, 51, 55]. A decrease in
risk was observed in two of three breast cancer studies,
which may reflect the improvement in radiation tech-
niques [31, 37]. On the other hand, an increase in MPC
risk was observed for a first non-Hodgkin lymphoma diag-
nosis in the mid-2000s than in the early 1990s, which may
suggest an adverse treatment effect with increased use of
nucleoside analogues (e.g. Fludarabine) at the end of the
1990s [34, 54]. The increase in the risk of MPCs following
thyroid cancer might occur as a consequence of aggressive
radiation treatment [42]. This is particularly concerning in
regard to the more recent increased detection and treat-
ment of microcarcinoma [79], largely considered to en-
compass overdiagnosis and overtreatment [72].
Together these findings suggest that most treatments
have not impacted the baseline risk of MPCs in persons
recently diagnosed with a primary cancer (post-1990),
with the exceptions of breast cancer (reduction), non-
Hodgkin lymphoma and thyroid cancer (increase).
Other factors to be considered
Changing patterns in lifestyle or environmental risk fac-
tors may also affect the value of SIRs over time. Tem-
poral trends in population exposure to carcinogenic
factors such as alcohol and tobacco consumption, dif-
fered across countries [48]. Any differences over time in
exposure in the reference population compared with the
population of cancer survivors could contribute to chan-
ging SIRs.
Limitations
Several factors limit the interpretation of our findings.
First, studies of all first cancer sites combined from the
USA and Australia did not cover the last 15 years. This
period is of particular relevance given the introduction
of nuclear medicine imaging, for example, PET/CT scan-
ning. Second, cancer survivor profile (age at first cancer
diagnosis, site of first cancer) may have varied according
to year of first cancer diagnosis and these factors may
contribute to changing SIRs [48]. For example, cancer
survivor profiles have changed with the implementation
of cancer screening programs. Third, variation in screen-
ing guidelines, follow-up care, management and treat-
ment for cancer across countries potentially affect the
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generalizability of the results. Fourth, some included
studies did not clearly specify the coding rules or defin-
ition of MPCs, which may result in misclassification and
less reliable estimation of the observed number of
MPCs. Fifth, different timeframes of the study cohorts
may limit the ability to evaluate long-term effects of
changing patterns in medical surveillance and treatment
of the primary cancer. Some studies published before
2000 lack sufficient data to compare SIRs pre-1990s and
post-1990s when treatment improved [32, 33, 45, 52].
Sixth, articles in languages other than English were ex-
cluded, which could lead to language bias. Last, although
we defined the age of the study population as adults,
some studies, mostly those using SEER cancer registries,
reported across all ages [7, 32, 34, 36, 39–45, 47, 49, 52,
54, 57]. However, childhood cancer survivors accounted
for a limited proportion of all cancer survivors (no more
than 2 % in SEER cancer registries), and the types of
cancer developed in children were limited [7], which
should minimise any impact on the overall results.
Conclusion
The overall risk of developing MPCs appears to have in-
creased in the USA and Australia from the 1980s to
2000 when all first cancer sites are combined. Increased
detection due to the more frequent use of diagnostic im-
aging and increased medical radiation exposure may be
potential explanations. Studies from Italy and France,
however, showed no significant change in MPC risk in
patients diagnosed with a first cancer after 2000. Given
the implementation of new cancer screening programs
and the growth of nuclear medical imaging (e.g. PET/CT
scanning) since 2000, continued long-term surveillance
is needed from non-European as well as European coun-
tries. Future studies are needed to assess the extent of
overdiagnosis and overtreatment among cancer survi-
vors relative to the general population, and thus to as-
sess whether there is potential for optimising follow-up
strategies.
Additional file
Additional file 1: STROBE Statement—Checklist of items that should be
included in reports of cohort studies. (DOC 87 kb)
Abbreviations
CI: Confidence Interval; IARC/IACR: International Agency for Research on
Cancer/International Association of Cancer Registries; MPCs: Multiple Primary
Cancers; PRISMA: Preferred Reporting Items for Systematic Reviews and
Meta-analyses; RR: Relative Risk; SEER: Surveillance, Epidemiology, and End
Results; SIR: Standardised Incidence Ratio; STROBE: Strengthening the
Reporting of Observational Studies in Epidemiology
Acknowledgements
We would like to thank the librarians at the University of Tasmania for their
advice on the search strategies for the electronic databases.
Funding
This study was not funded by any outside source.
Availability of data and materials
All data generated or analysed during this study are included in this
published article.
Authors’ contribution
The first author (YY) conducted the search strategy, the data extraction, the
narrative analysis and drafted the paper. The senior author (AV) created the
scope of the review, defined the inclusion and exclusion criteria with YY and
evaluated the quality of the included studies with YY. AV and AN edited all
drafts of the paper. KW gave additional advice on the interpretation of the
results. All authors approved the final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Received: 4 July 2016 Accepted: 24 October 2016
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer
statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama
A, Visser O, Brenner H, Ardanaz E. Cancer survival in Europe 1999–2007 by
country and age: results of EUROCARE-5—a population-based study.
Lancet Oncol. 2014;15(1):23–34.
3. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R,
Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014.
CA Cancer J Clin. 2014;64(4):252–71.
4. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang X-S, Bannon F,
Ahn JV, Johnson CJ, Bonaventure A. Global surveillance of cancer survival
1995–2009: analysis of individual data for 25 676 887 patients from 279
population-based registries in 67 countries (CONCORD-2). Lancet.
2015;385(9972):977–1010.
5. Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer
prevalence: a growing challenge in long-term survivorship. Cancer
Epidemiol Biomarkers Prev. 2007;16(3):566–71.
6. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends,
and multiple primary cancer analyses from the Surveillance, Epidemiology,
and End Results (SEER) Program. Oncologist. 2007;12(1):20–37.
7. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker
MA, Fraumeni JF Jr (eds). New malignancies among cancer survivors. SEER
cancer registries, 1973–2000. NIH Publ. No. 05-5302. Bethesda: National
Cancer Institute; 2006.
8. Working GR. International rules for multiple primary cancers (ICD-0 third
edition). Eur J Cancer Prev. 2005;14(4):307.
9. Mettler Jr FA, Bhargavan M, Faulkner K, Gilley DB, Gray JE, Ibbott GS, Lipoti
JA, Mahesh M, McCrohan JL, Stabin MG. Radiologic and Nuclear Medicine
Studies in the United States and Worldwide: Frequency, Radiation Dose,
and Comparison with Other Radiation Sources—1950–2007 1. Radiology.
2009;253(2):520–31.
10. Miglioretti DL, Smith-Bindman R. Overuse of computed tomography and
associated risks. Am Fam Physician. 2011;83(11):1252–4.
11. United Nations. Scientific Committee on the Effects of Atomic Radiation.
Sources and effects of ionizing radiation: sources. Vol. 1. United Nations
Publications; 2000.
12. Linet MS, Slovis TL, Miller DL, Kleinerman R, Lee C, Rajaraman P, Berrington
de Gonzalez A. Cancer risks associated with external radiation from
diagnostic imaging procedures. CA Cancer J Clin. 2012;62(2):75–100.
13. Colt HG, Murgu SD, Korst RJ, Slatore CG, Unger M, Quadrelli S. Follow-up
and surveillance of the patient with lung cancer after curative-intent
therapy: Diagnosis and management of lung cancer, 3rd ed: American
Ye et al. BMC Cancer  (2016) 16:849 Page 15 of 17
College of Chest Physicians evidence-based clinical practice guidelines.
Chest. 2013;143(5 Suppl):e437S–454S.
14. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F,
Hantel A, Henry NL, Muss HB, Smith TJ. Breast cancer follow-up and
management after primary treatment: American Society of Clinical
Oncology clinical practice guideline update. J Clin Oncol. 2013;31(7):961–5.
15. Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, Petrelli
NJ, Ryan K, Schrag DH, Wong SL. Follow-up care, surveillance protocol, and
secondary prevention measures for survivors of colorectal cancer: American
Society of Clinical Oncology clinical practice guideline endorsement. J Clin
Oncol. 2013;31(35):4465–70.
16. Mathews JD, Forsythe AV, Brady Z, Butler MW, Goergen SK, Byrnes GB, et al.
Cancer risk in 680 000 people exposed to computed tomography scans in
childhood or adolescence: data linkage study of 11 million Australians. BMJ.
2013;346:f2360.
17. Lorigan P, Califano R, Faivre-Finn C, Howell A, Thatcher N. Lung cancer after
treatment for breast cancer. Lancet Oncol. 2010;11(12):1184–92.
18. Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for
Hodgkin’s lymphoma: a systematic review. Lancet Oncol. 2005;6(10):773–9.
19. Pui C-H, Howard SC. Current management and challenges of malignant
disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008;9(3):257–68.
20. Pui C-H, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK, Mirro Jr J,
Kalwinsky DK, Dahl GV, Murphy SB. Secondary acute myeloid leukemia in
children treated for acute lymphoid leukemia. N Engl J Med. 1989;321(3):136–42.
21. Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol
Biomarkers Prev. 2006;15(11):2020–6.
22. Neugut AI, Robinson E, Meadows AT: Multiple primary cancers: Lippincott
Williams & Wilkins; 1999.
23. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant
neoplasms: assessment and strategies for risk reduction. J Clin Oncol.
2012;30(30):3734–45.
24. Cybulski C, Nazarali S, Narod SA. Multiple primary cancers as a guide to
heritability. Int J Cancer J Int du cancer. 2014;135(8):1756–63.
25. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. Ann Intern
Med. 2009;151(4):264–9.
26. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP,
Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for
reporting systematic reviews and meta-analyses of studies that evaluate
health care interventions: explanation and elaboration. Ann Intern Med.
2009;15(4):W-65–94.
27. Schoenberg BS, Myers MH. Statistical methods for studying multiple primary
malignant neoplasms. Cancer. 1977;40(S4):1892–8.
28. Breslow N, Day N. IARC Scientific Publications No. 82: Statistical
Methods in Cancer Research Vol. II: The Design and Analysis of
Cohort Studies. International Agency for Research on Cancer: Lyon,
France 1987.
29. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke
JP. The Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement: guidelines for reporting observational
studies. Lancet (London, England). 2007;370(9596):1453–7.
30. Johnson C, Peace S, Adamo P, Fritz A, Percy-Laurry A, Edwards B. The 2007
Multiple Primary and Histology Coding Rules. Bethesda, MD: National
Cancer Institute. Surveillance, Epidemiology and End Results Program. 2007.
31. Brown LM, Chen BE, Pfeiffer RM, Schairer C, Hall P, Storm H, Pukkala E,
Langmark F, Kaijser M, Andersson M, et al. Risk of second non-
hematological malignancies among 376,825 breast cancer survivors. Breast
Cancer Res Treat. 2007;106(3):439–51.
32. Coleman M, Bell C, Fraser P. Second primary malignancy after Hodgkin’s
disease, ovarian cancer and cancer of the testis: a population-based cohort
study. Br J Cancer. 1987;56(3):349.
33. Levi F, Randimbison L, Te VC, Erler G, La Vecchia C. Second primary tumors
after prostate carcinoma. Cancer. 1999;86(8):1567–70.
34. Lorenzo Bermejo J, Pukkala E, Johannesen TB, Sundquist J, Hemminki K.
Age-time risk patterns of solid cancers in 60 901 non-Hodgkin
lymphoma survivors from Finland, Norway and Sweden. Br J Haematol.
2014;164(5):675–83.
35. Rebora P, Czene K, Antolini L, Gambacorti Passerini C, Reilly M,
Valsecchi MG. Are chronic myeloid leukemia patients more at risk for
second malignancies? A population-based study. Am J Epidemiol.
2010;172(9):1028–33.
36. Schollkopf C, Rosendahl D, Rostgaard K, Pipper C, Hjalgrim H. Risk of second
cancer after chronic lymphocytic leukemia. Int J Cancer. 2007;121(1):151–6.
37. Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, Andersen A,
Brewster DH, Pukkala E, McBride ML, et al. Risk of second cancer among
women with breast cancer. Int J Cancer. 2006;118(9):2285–92.
38. Molina-Montes E, Pollan M, Payer T, Molina E, Davila-Arias C, Sanchez
MJ. Risk of second primary cancer among women with breast cancer:
A population-based study in Granada (Spain). Gynecol Oncol.
2013;130(2):340–5.
39. Bao X, Cao L, Piao H, Xie L. Treatment-related secondary cancer in
malignant meningiomas: A population-based study. J Cancer Res Clin
Oncol. 2014;140(4):583–8.
40. Hisada M, Chen BE, Jaffe ES, Travis LB. Second cancer incidence and cause-
specific mortality among 3104 patients with hairy cell leukemia: a
population-based study. J Natl Cancer Inst. 2007;99(3):215–22.
41. Howard RA, Dores GM, Curtis RE, Anderson WF, Travis LB. Merkel cell
carcinoma and multiple primary cancers. Cancer Epidemiol Biomark Prev.
2006;15(8):1545–9.
42. Kim C, Bi X, Pan D, Chen Y, Carling T, Ma S, Udelsman R, Zhang Y. The risk
of second cancers after diagnosis of primary thyroid cancer is elevated in
thyroid microcarcinomas. Thyroid. 2013;23(5):575–82.
43. Razavi P, Rand KA, Cozen W, Chanan-Khan A, Usmani S, Ailawadhi S.
Patterns of second primary malignancy risk in multiple myeloma patients
before and after the introduction of novel therapeutics. Blood Cancer J.
2013, 3(6).
44. Zhu G, Chen Y, Zhu Z, Lu L, Bi X, Deng Q, et al. Risk of second primary
cancer after treatment for esophageal cancer: a pooled analysis of nine
cancer registries. Dis Esophagus. 2012;25(6):505–11.
45. Tsukuma H, Fujimoto I, Hanai A, Hiyama T, Kitagawa T, Kinoshita N.
Incidence of second primary cancers in Osaka residents, Japan, with
special reference to cumulative and relative risks. Jpn J Cancer Res.
1994;85(4):339–45.
46. Youlden DR, Baade PD: The relative risk of second primary cancers in
Queensland, Australia: A retrospective cohort study. BMC cancer. 2011, 11.
47. Scélo G, Boffetta P, Autier P, Hemminki K, Pukkala E, Olsen JH, et al.
Associations between ocular melanoma and other primary cancers: an
international population-based study. Int J Cancer. 2007;120(1):152–9.
48. Jegu J, Colonna M, Daubisse-Marliac L, Tretarre B, Ganry O, Guizard AV,
Bara S, Troussard X, Bouvier V, Woronoff AS, et al. The effect of patient
characteristics on second primary cancer risk in France. BMC Cancer.
2014;14:94.
49. Cho YY, Lim J, Oh CM, Ryu J, Jung KW, Chung JH, Won YJ, Kim SW. Elevated
risks of subsequent primary malignancies in patients with thyroid cancer: a
nationwide, population-based study in Korea. Cancer. 2015;121(2):259–68.
50. Jegu J, Binder-Foucard F, Borel C, Velten M. Trends over three decades of
the risk of second primary cancer among patients with head and neck
cancer. Oral Oncol. 2013;49(1):9–14.
51. Federico M, Zinzani PL, Frassoldati A, Vinceti M, Modè A, Annino L, Chisesi T,
Pagnucco G, Invernizzi R, Spriano M. Risk of second cancer in patients with
hairy cell leukemia: long-term follow-up. J Clin Oncol. 2002;20(3):638–46.
52. Sankila R, Pukkala E, Teppo L. Risk of subsequent malignant neoplasms
among 470,000 cancer patients in Finland, 1953–1991. Int J Cancer.
1995;60(4):464–70.
53. Guan X, Jin Y, Chen Y, Jiang Z, Liu Z, Zhao Z, Yan P, Wang G, Wang X.
The Incidence characteristics of second primary malignancy after
diagnosis of primary colon and rectal cancer: a population based study.
PLoS One. 2015;10(11):e0143067.
54. Rossi C, Jégu J, Mounier M, Dandoit M, Colonna M, Daubisse-Marliac L,
Trétarre B, Ganry O, Guizard A-V, Bara S. Risk assessment of second primary
cancer according to histological subtype of non-Hodgkin lymphoma. Leuk
Lymphoma. 2015;56(10):2876–82.
55. Joung JY, Lim J, Oh C-M, Jung K-W, Cho H, Kim SH, Seo HK, Park WS,
Chung J, Lee KH. Risk of second primary cancer among prostate
cancer patients in Korea: a population-based cohort study. PLoS One.
2015;10(10):e0140693.
56. Muller J, Grosclaude P, Lapôtre‐Ledoux B, Woronoff AS, Guizard AV, Bara S,
Colonna M, Troussard X, Bouvier V, Trétarre B: Trends in the risk of second
primary cancer among bladder cancer survivors: a population‐based cohort
of 10 047 patients. BJU international 2015.
57. AIRTUM Working Group. Italian cancer figures, report 2013: Multiple
tumours. Epidemiol Prev. 2013;37(4–5 Suppl 1):1.
Ye et al. BMC Cancer  (2016) 16:849 Page 16 of 17
58. Weir HK, Johnson CJ, Thompson TD. The effect of multiple primary rules on
population-based cancer survival. Cancer Causes Control. 2013;24(6):1231–42.
59. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst.
2010;102(9):605–13.
60. Australian Institute of Health and Welfare. Cancer in Australia: an overview
2014. Cancer series no. 90. Cat. no. CAN 88. Canberra: AIHW; 2014.
61. Breen N, Wagener DK, Brown ML, Davis WW, Ballard-Barbash R. Progress in
cancer screening over a decade: results of cancer screening from the 1987,
1992, and 1998 National Health Interview Surveys. J Natl Cancer Inst.
2001;93(22):1704–13.
62. Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz
CD, Sener S, Saslow D, Eyre HJ. American Cancer Society guidelines for the
early detection of cancer. CA Cancer J Clin. 2002;52(1):8–22.
63. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening
practices in the United States. Cancer. 2003;97(6):1528–40.
64. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer
and prostate cancer. JAMA. 2009;302(15):1685–92.
65. Patz EF, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemägi MC, Chiles C,
Black WC, Aberle DR. Overdiagnosis in low-dose computed tomography
screening for lung cancer. JAMA Intern Med. 2014;174(2):269–74.
66. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T,
Colditz GA, Gould MK, Jett JR. Benefits and harms of CT screening for lung
cancer: a systematic review. JAMA. 2012;307(22):2418–29.
67. Bleyer A, Welch HG. Effect of three decades of screening mammography on
breast-cancer incidence. N Engl J Med. 2012;367(21):1998–2005.
68. Vogel VG. Identifying and screening patients at risk of second cancers.
Cancer Epidemiol Biomark Prev. 2006;15(11):2027–32.
69. Corkum M, Hayden JA, Kephart G, Urquhart R, Schlievert C, Porter G.
Screening for new primary cancers in cancer survivors compared to non-
cancer controls: a systematic review and meta-analysis. J Cancer Surviv.
2013;7(3):455–63.
70. Brenner DJ, Hall EJ. Computed tomography—an increasing source of
radiation exposure. N Engl J Med. 2007;357(22):2277–84.
71. Kattlove H, Winn RJ. Ongoing care of patients after primary treatment for
their cancer. CA Cancer J Clin. 2003;53(3):172–96.
72. Morgan DJ, Dhruva SS, Wright SM, Korenstein D. Update on medical
practices that should be questioned in 2015. JAMA Intern Med.
2015;175(12):1960–4.
73. UNSCEAR S. Effects of Ionizing Radiation: 2000 Report to the General Assembly,
with Scientific Annexes, Vol. II: Effects. United Nations, New York. 2000
74. de Gonzalez AB, Darby S. Risk of cancer from diagnostic X-rays: estimates
for the UK and 14 other countries. Lancet. 2004;363(9406):345–51.
75. Smith-Bindman R, Lipson J, Marcus R, Kim K-P, Mahesh M, Gould R, de
González AB, Miglioretti DL. Radiation dose associated with common
computed tomography examinations and the associated lifetime
attributable risk of cancer. Arch Intern Med. 2009;169(22):2078–86.
76. Shuryak I, Sachs RK, Brenner DJ. Cancer risks after radiation exposure in
middle age. J Natl Cancer Inst. 2010;102(21):1628–36.
77. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L,
Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC. New guidelines
to evaluate the response to treatment in solid tumors. J Natl Cancer Inst.
2000;92(3):205–16.
78. Sodickson A, Baeyens PF, Andriole KP, Prevedello LM, Nawfel RD,
Hanson R, Khorasani R. Recurrent CT, cumulative radiation exposure,
and associated radiation-induced cancer risks from CT of adults 1.
Radiology. 2009;251(1):175–84.
79. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United
States, 1973–2002. JAMA. 2006;295(18):2164–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ye et al. BMC Cancer  (2016) 16:849 Page 17 of 17
